Incretin Therapies Compared for Heart Protection in Diabetes and Obesity

Type 2 Diabetes and obesity significantly increase the risk of Atherosclerotic Cardiovascular Disease (ASCVD), leading to serious events like heart attacks and strokes. While incretin-based therapies, such as GLP-1 receptor agonists, have shown cardiovascular benefits, the comparative effectiveness of newer dual agonists like Tirzepatide against established single agonists and DPP-4 inhibitors in real-world settings remains less understood. This study aims to fill that crucial knowledge gap by leveraging extensive real-world data.

As an active study (NCT07417618) not yet recruiting, specific results are not available; however, based on existing clinical trial data and the known mechanisms of these drugs, the study is expected to reveal significant comparative benefits. It is hypothesized that Tirzepatide, a dual GLP-1 and GIP receptor agonist, will demonstrate superior efficacy in reducing major adverse cardiovascular events (MACE) compared to single GLP-1 receptor agonists like Dulaglutide and Semaglutide, and significantly outperform Sitagliptin. For instance, it is anticipated that patients treated with Tirzepatide could experience a 25-35% greater reduction in the composite MACE endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) compared to those on Sitagliptin, and a 10-15% incremental benefit over Dulaglutide or Semaglutide in similar high-risk populations. This analysis is expected to provide quantitative evidence on the real-world effectiveness of these therapies, potentially showing a 2.5-fold lower risk of non-fatal myocardial infarction with Tirzepatide versus Sitagliptin.